金城医药：公司实控人兼董事长赵叶青因操纵公司股票收证监会处罚

Core Viewpoint - Jin Cheng Pharmaceutical (300233) has been penalized by the China Securities Regulatory Commission (CSRC) for stock manipulation involving its actual controller Zhao Yeqing and others, leading to fines and market bans for the involved parties [1][2] Group 1: Regulatory Actions - The CSRC has concluded an investigation into Zhao Yeqing, Wang Zhen, and Liu Feng for manipulating the stock of Shandong Jin Cheng Pharmaceutical Group Co., Ltd., using a total of 104 accounts for trading [1] - Fines imposed include 3 million yuan in total, with Zhao Yeqing responsible for 1.5 million yuan, Wang Zhen for 1.2 million yuan, and Liu Feng for 300,000 yuan [1] Group 2: Market Bans - Zhao Yeqing has been subjected to a 4-year market ban, while Wang Zhen faces a 3-year ban, preventing them from engaging in securities business or holding positions in any listed or non-listed public companies during this period [2] - The bans are in accordance with the 2005 Securities Law and related regulations [2] Group 3: Corporate Governance Changes - Following the regulatory actions, Zhao Yeqing has submitted a resignation report, stepping down from his positions as Chairman, Director, and roles in the board's specialized committees due to personal reasons [2] - His resignation will take effect upon delivery of the report to the board, after which he will no longer hold any position within the company [2]